Secretory granule exocytosis and its amplification by cAMP in pancreatic β-cells
Diabetology International · 2022-07 · 13 (3) · 471-479
DOI: 10.1007/s13340-022-00580-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetology International, online erschienen am 01.04.2022. Verfasst von Mototsugu Nagao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603 J…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The sequence of events for secreting insulin in response to glucose in pancreatic β-cells is termed "stimulus-secretion coupling". The core of stimulus-secretion coupling is a process which generates electrical activity in response to glucose uptake and causes Ca2+ oscillation for triggering exocytosis of insulin-containing secretory granules. Prior to exocytosis, the secretory granules are mobilized and docked to the plasma membrane and primed for fusion with the plasma membrane. Together with the final fusion with the plasma membrane, these steps are named the exocytosis process of insulin secretion. The steps involved in the exocytosis process are crucial for insulin release from β-cells and considered indispensable for glucose homeostasis. We recently confirmed a signature of defective exocytosis process in human islets and β-cells of obese donors with type 2 diabetes (T2D). Furthermore, cyclic AMP (cAMP) potentiates glucose-stimulated insulin secretion through mechanisms including accelerating the exocytosis process. In this mini-review, we aimed to organize essential knowledge of the secretory granule exocytosis and its amplification by cAMP. Then, we suggest the fatty acid translocase CD36 as a predisposition in β-cells for causing defective exocytosis, which is considered a pathogenesis of T2D in relation to obesity. Finally, we propose potential therapeutics of the defective exocytosis based on a CD36-neutralizing antibody and on Apolipoprotein A-I (ApoA-I), for improving β-cell function in T2D.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603 Japan.
- Department of Clinical Sciences Malmö, Islet Cell Exocytosis, Lund University Diabetes Centre, Lund University, CRC 91-11, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden.
- Novo Nordisk A/S, Copenhagen, Denmark.
ORCID-Profile: Mototsugu Nagao
Zitieren
APA
Nagao, M., Lagerstedt, J. O., & Eliasson, L. (2022). Secretory granule exocytosis and its amplification by cAMP in pancreatic β-cells. Diabetology International, 13(3), 471-479. https://doi.org/10.1007/s13340-022-00580-3
Vancouver
Nagao M, Lagerstedt JO, Eliasson L. Secretory granule exocytosis and its amplification by cAMP in pancreatic β-cells. Diabetology International. 2022;13(3):471-479. doi:10.1007/s13340-022-00580-3
BibTeX
@article{Nagao2022,
author = {Nagao, Mototsugu and Lagerstedt, Jens O and Eliasson, Lena},
title = {Secretory granule exocytosis and its amplification by cAMP in pancreatic β-cells},
journal = {Diabetology International},
year = {2022},
volume = {13},
number = {3},
pages = {471--479},
doi = {10.1007/s13340-022-00580-3}
}
EUVIMED